Author

K. M. Appleton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:statistical model· 1

Frequent Co-Authors

R. R. Neubig· 2 shared S. A. Misek· 2 shared T. S. Dexheimer· 2 shared C. C. Palsuledesai· 1 shared E. M. Lisabeth· 1 shared J. Zagorski· 1 shared K. Gallo· 1 shared M. Blake· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

R. R. Neubig

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell lines

K. M. Appleton, C. C. Palsuledesai, S. A. Misek, M. Blake, J. Zagorski, T. S. Dexheimer, R. R. Neubig

This study shows that inhibiting the Rho/MRTF pathway with CCG-222740 enhances trametinib's effectiveness in NRAS-mutant melanoma cell lines by reducing cell viability and clonogenicity.

bioRxiv · Sep 19, 2019Cancer Biology

Rho-mediated gene transcription promotes BRAF inhibitor resistance in de-differentiated melanoma cells

S. A. Misek, K. M. Appleton, T. S. Dexheimer, E. M. Lisabeth, R. Lo, S. D. Larsen, K. Gallo, R. R. Neubig

This study identifies RhoA-mediated gene transcription as a mechanism of BRAF inhibitor resistance in melanoma, showing that targeting this pathway can re-sensitize resistant cells to vemurafenib.

bioRxiv · Mar 31, 2019 · PreprintCancer Biology